Recent work from Angela Brodie’s laboratory indicates a HER2-dependent upregulation of miR-181a in letrozole-resistant ERα-negative/HER2-positive breast cancer cells, and indicates that miR-181a expression is increased in ERα-negative/HER2-positive and ERα-positive/HER2-positive clinical samples [98]. The gene discussed is ESR1; the disease is breast cancer.